Department of Research and Development, Finnish Red Cross Blood Service, Helsinki, Finland.
Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki University Central Hospital, Helsinki, Finland.
HLA. 2016 May;87(5):350-5. doi: 10.1111/tan.12770. Epub 2016 Mar 10.
Loss of heterozygosity (LOH) has been reported to cause false human leukocyte antigen (HLA) homozygous typing results in pre-transplant patients suffering from haematological malignancies, who in fact are HLA heterozygous. This poses a challenge for histocompatibility testing, as a stem cell graft from a genuinely HLA homozygous donor to a mistyped patient may lead to acute life-threatening graft-vs-host disease. LOH in the HLA region on chromosome 6 is known to be quite common in solid tumours, helping malignant cells to escape T-cell surveillance, but the incidence in haematological malignancies is less well known and the estimates vary. Here we report LOH in the HLA region of five patients with haematological malignancy. We found considerable differences in sensitivity between the three different HLA typing methods used in our laboratory: SSP was clearly the most sensitive method for detecting the lost haplotype, followed by rSSO, while SBT was the least sensitive technique. A subsequent, retrospective genotyping of 65 HLA homozygous haematological patients by SSP method showed no mistyped LOH cases in our laboratory in the past 10 years. The frequency of HLA homozygosity was found to be similar between haematological patients and control groups. It is important for an HLA laboratory to be aware of the differences in various HLA typing techniques' sensitivity for detecting an under-represented haplotype between HLA typing techniques when genotyping patients with haematological diseases. It is advisable for HLA laboratories to have at least two different methods with different sensitivities in their repertoire to be able to retype samples when a false homozygous result is suspected.
杂合性缺失 (LOH) 已被报道会导致接受造血系统恶性肿瘤移植前治疗的患者出现 HLA 纯合假阳性结果,而这些患者实际上是 HLA 杂合子。这对组织相容性检测构成了挑战,因为来自真正 HLA 纯合供体的干细胞移植到被错误定型的患者中可能导致危及生命的急性移植物抗宿主病。已知 6 号染色体 HLA 区域的 LOH 在实体肿瘤中非常常见,有助于恶性细胞逃避 T 细胞监测,但在血液恶性肿瘤中的发生率知之甚少,估计值也各不相同。在这里,我们报告了五例血液恶性肿瘤患者 HLA 区域的 LOH。我们发现我们实验室使用的三种不同 HLA 分型方法之间的灵敏度存在相当大的差异:SSP 显然是检测丢失单体型最敏感的方法,其次是 rSSO,而 SBT 是最不敏感的技术。随后,通过 SSP 方法对 65 例 HLA 纯合血液恶性肿瘤患者进行回顾性基因分型,在过去 10 年中,我们实验室没有发现 HLA 纯合假阳性的 LOH 病例。发现血液患者和对照组之间 HLA 纯合子的频率相似。对于 HLA 实验室来说,当对血液疾病患者进行基因分型时,了解不同 HLA 分型技术检测代表性不足的单体型的灵敏度差异非常重要。建议 HLA 实验室在其检测方法中至少具有两种不同的方法,以不同的灵敏度,以便在怀疑出现假纯合结果时能够重新检测样本。